[{"orgOrder":0,"company":"Rhine Pharma","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Demerger","leadProduct":"188Re-PSMA","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Rhine Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Rhine Pharma \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"14","companyTruncated":"Rhine Pharma \/ Telix Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by Rhine Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Manufacturing 2024
                          Not Confirmed
                          Pharma Manufacturing 2024
                          Not Confirmed

                          Details : Rhine Pharma has the mission of expanding global access to innovative radiopharmaceuticals for cancer imaging and treatment using two generator-produced isotopes, 99mTc and 188Re.

                          Brand Name : RHN001-Tx

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : 188Re-PSMA

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Telix Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Demerger

                          blank